Abhishek Kansara is an Endocrinology/Metabolic physician affiliated with Houston Methodist. OpenAlex indexes 29 publications with 1,728 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6550 Fannin St
Suite 1101
Houston, TX 77030
Telephone
713-441-4451Registry record last updated 30 Oct 2018.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20252 payments
- Medtronic, Inc.Program year20252 payments
- Madrigal PharmaceuticalsProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
77.9%GLP-1 receptor agonist30.3%Ozempic61%Mounjaro22%Trulicity12%Rybelsus5%Part D≥90 patientsInsulin Analog21.6%Humalog Kwikpen U-10017%Lantus Solostar12%Novolog Flexpen11%Humalog11%Tresiba Flextouch U-10010%Insulin Lispro Kwikpen U-1008%Novolog6%Toujeo Solostar5%Basaglar Kwikpen U-1005%Fiasp Flextouch5%Lyumjev Kwikpen U-1005%Tresiba Flextouch U-2003%Admelog Solostar2%Part D<11 patients+ 6 more classes in this area
Hormonal (systemic)
13.1%l-Thyroxine11.5%Levothyroxine Sodium75%Synthroid25%Part D≥65 patientsThyroid Hormone Synthesis Inhibitor0.8%Methimazole100%Part D<11 patients+ 1 more class in this area
Cardiovascular
5.6%Statin5.1%Atorvastatin Calcium55%Rosuvastatin Calcium45%Part D≥23 patientsPCSK9 Inhibitor0.6%Repatha Sureclick100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Unified System-Wide Electronic Dashboard for Inpatient Glucose Management Across a Large Health System
Journal of Diabetes Science and Technology
2026 - Medical Management of Obesity: Current Trends and Future Perspectives
Methodist DeBakey Cardiovascular Journal
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Bita Esmaeli, MD
Houston Methodist
Sherif Nagueh, MD
Houston Methodist
Neal Kleiman, MD
Houston Methodist
Miguel Quinones, MD
Houston Methodist
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”